NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Attovia Therapeutics ATTO

Attovia Therapeutics listed on Nasdaq on 5 Aug 2026 and is not in the S&P 500. It is worth $712 million. Its price history starts on 7 Aug 2026. Its board is not in our data yet.

Listed
5 Aug 2026 on Nasdaq, IPO filings and terms
Headquarters
San Carlos, CA
Market cap
$712M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Financial history

Twelve months to 30 Jun 2026, from Attovia Therapeutics' quarterly filings.

Quarters since Sep 2025

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Sep 2025 to Jun 2026

Not reported for enough quarters.

Attovia Therapeutics' market cap since August 2026

Weekly, up to 13 Nov 2026

Sep 2026OctNov$690M

Board and leadership

Board and officers

Attovia Therapeutics' board is not in our data yet. It listed on 5 Aug 2026 and has not filed a proxy statement. See its 8-K filings.

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $2.3 million of stock in 1 sale and bought $10.3 million in 2 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
6 Aug 2026BuyColin WalshDirectorDirectorBuy500,000$8.5M
5 Aug 2026SaleColin WalshDirectorDirectorSale105,807$2.3M
5 Aug 2026BuyColin WalshDirectorDirectorBuy85,000$1.8M

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 large insider sale in the last two years.

Left the company or board 0Appointed 0WARN layoff notices 0Large insider sales 1Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Attovia Therapeutics' insider sales.

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months. 13F holdings: Attovia Therapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.